A Double-Blind, Placebo Controlled, Randomised Phase II Trial of Probucol in Alzheimer’s Disease (PIA-Study): The Impact on Cognition

Probucol in Alzheimer’s Disease (PIA-Study) aims to test Probucol, a potential new treatment for Alzheimer’s disease. 

Previously used to treat cardiovascular disease and stroke, Probucol shows promise in supporting memory performance in Alzheimer’s patients safely. 
 

The PIA trial spans 104 weeks (2 years) of daily oral dosing of either Probucol or a placebo. Participants will attend 14 clinic visits and receive 7 phone calls over the study period.

You may qualify for pre-trial screening if you meet in the following criteria:

• Have been diagnosed with Alzheimer’s disease or suffer from memory issues
• Are over 18 and under 85 years of age.
• Have someone such as a spouse, partner, family member, friend or carer who can assist with designated parts of the study (they should be someone who has frequent contact with the person with Alzheimer’s/memory issues and with whom the person feels comfortable)
• Are willing to commit to a 2 year trial that involves taking daily medication, attending 14 study-related appointments, and receive 7 phone calls, pre-trial screening and post-trial evaluations. 

For further information please visit our website.

This study is being conducted at three sites; 

Perth site: Curtin University - Curtin Health Innovation Research Institute 

Hobart site: University of Tasmania - Wicking Dementia Research and Education Centre

Adelaide site: The Queen Elizabeth Hospital - CALHN Memory Trials Unit